1-10 of 10
James Cooper
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Joshua Richter, Sheeba K. Thomas, Amrita Y Krishnan, Jacob P. Laubach, Adam D. Cohen, Suzanne Trudel, Luciano J. Costa, Nizar J. Bahlis, Peter A. Forsberg, Rayan Kaedbey, Rafael Fonseca, Andrew Spencer, Paula Rodríguez-Otero, Maria-Victoria Mateos, Chihunt Wong, James Cooper, Tulika Tyagi, Rin Nakamura, Voleak Choeurng, Alexander M. Lesokhin
Journal: Blood
Blood (2024) 144 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2024-199542
Published: 2024
Journal Articles

Evaluation of Immune Reconstitution in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Cevostamab in Phase I Study GO39775

Jane Miglo, Voleak Choeurng, Rin Nakamura, James Cooper
Journal: Blood
Blood (2023) 142 (Supplement 1): 4759.
https://doi.org/10.1182/blood-2023-180059
Published: 2023
Journal Articles

Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

Suzanne Trudel, Nizar J. Bahlis, Andrew Spencer, Rayan Kaedbey, Paula Rodriguez Otero, Simon J Harrison, Chihunt Wong, Grant R. Goodman, Rin Nakamura, Voleak Choeurng, James Cooper, Maria-Victoria Mateos
Journal: Blood
Blood (2022) 140 (Supplement 1): 1363–1365.
https://doi.org/10.1182/blood-2022-159381
Published: 2022
Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Alexander M Lesokhin, Joshua Richter, Suzanne Trudel, Adam D Cohen, Andrew Spencer, Peter A Forsberg, Jacob P Laubach, Sheeba K Thomas, Nizar J. Bahlis, Luciano J. Costa, Paula Rodriguez Otero, Maria-Victoria Mateos, Jesus G Berdeja, Rayan Kaedbey, Amrita Y. Krishnan, Rafael Fonseca, Voleak Choeurng, James Cooper, Teiko Sumiyoshi, Chihunt Wong, Simon J Harrison
Journal: Blood
Blood (2022) 140 (Supplement 1): 4415–4417.
https://doi.org/10.1182/blood-2022-157547
Published: 2022
Journal Articles

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Suzanne Trudel, Adam D Cohen, Amrita Y. Krishnan, Rafael Fonseca, Andrew Spencer, Jesús G. Berdeja, Alexander Lesokhin, Peter A Forsberg, Jacob P. Laubach, Luciano J. Costa, Paula Rodriguez-Otero, Rayan Kaedbey, Joshua Richter, Maria-Victoria Mateos, Sheeba K Thomas, Chihunt Wong, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Simon J Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 157.
https://doi.org/10.1182/blood-2021-147983
Published: 2021
Journal Articles

Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Rin Nakamura, Sean Lear, Deanna Wilson, Hartmut Koeppen, Anjali Vaze, Suzanne Trudel, MD MSC, FRCPC, Andrew Spencer, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Adam D. Cohen, MD, Bernard M Fine, Mengsong Li, James Cooper, Teiko Sumiyoshi
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-136980
Published: 2020
Journal Articles

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Adam D. Cohen, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Amrita Krishnan, MD, Rafael Fonseca, MD, Peter A Forsberg, MD, Andrew Spencer, Jesus G. Berdeja, MD, Jacob P. Laubach, MD, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M Fine, Suzanne Trudel
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-136985
Published: 2020
Journal Articles

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Clinical Trials & Observations
Thomas Winkler, Xing Fan, James Cooper, Ronan Desmond, David J. Young, Danielle M. Townsley, Phillip Scheinberg, Sophia Grasmeder, Andre Larochelle, Marie Desierto, Janet Valdez, Jennifer Lotter, Colin Wu, Ruba N. Shalhoub, Katherine R. Calvo, Neal S. Young, Cynthia E. Dunbar
Journal: Blood
Blood (2019) 133 (24): 2575–2585.
https://doi.org/10.1182/blood.2019000478
Published: 2019
Journal Articles

Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells

Xin Zhao, Shouguo Gao, Zhijie Wu, Sachiko Kajigaya, Xingmin Feng, Qingguo Liu, Danielle M. Townsley, James Cooper, Jinguo Chen, Keyvan Keyvanfar, Maria del Pilar Fernandez Ibanez, Xujing Wang, Neal S. Young
Journal: Blood
Blood (2017) 130 (25): 2762–2773.
https://doi.org/10.1182/blood-2017-08-803353
Published: 2017
Includes: Supplemental data
Journal Articles

No Association between Age of Transfused Red Cells and 30-Day Mortality in Massively Transfused Patients: Results from the Australian and New Zealand Massive Transfusion Registry

Nicholas Saadah, BS, Erica Wood, Michael Bailey, D. James Cooper, Craig French, Zoe McQuilten
Journal: Blood
Blood (2017) 130 (Supplement 1): 3728.
https://doi.org/10.1182/blood.V130.Suppl_1.3728.3728
Published: 2017